Compass Therapeutics, Inc.

NASDAQ•CMPX

CEO: Dr. Thomas J. Schuetz M.D., Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2021-04-05

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

連絡先情報

80 Guest Street, Suite 601, Boston, MA, 02135, United States

617-500-8099

www.compasstherapeutics.com

時価総額

$786.85M

PER (TTM)

-12.0

19.7

配当利回り

52週高値

$6.88

52週安値

$1.33

52週レンジ

79%

順位65Top 96.0%

1.6

F-Score

改良版 Piotroski 分析

7年ファンダメンタル

弱い • 1.6 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2019-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.10+31.23%

直近4四半期の推移

フリーCF

$0.00-100.00%

直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Strong Liquidity Position Maintained Cash, equivalents, and securities total $220M USD; expected to fund operations into 2028 based on current plans.

R&D Spending Rises Sharply Nine-month R&D expenses reached $42.3M USD, increasing $13.0M USD, driven by pipeline advancement costs.

Recent Equity Financing Secured August 2025 offering provided $129.3M USD net proceeds, bolstering capital resources for ongoing clinical development.

Increased Net Loss Reported Nine-month net loss widened to $(50.8)M USD from $(34.3)M USD, reflecting increased operating expenses.

リスク要因

Continued Operating Losses Expected Expect significant expenses for years ahead advancing pipeline; profitability timing remains highly unpredictable.

Drug Pricing Executive Actions New executive orders target drug price reduction, potentially impacting future reimbursement and commercial viability.

Global Economic Uncertainty Risk Global market instability, inflation, and trade disputes pose risks that may adversely affect financial results.

Dependence on Future Funding Substantial additional funding required to support operations; failure to raise capital risks delaying development efforts.

見通し

Tovecimig Data Expected Q1 2026 Overall survival and progression-free survival analysis for Tovecimig BTC Phase 2/3 study anticipated in late Q1 2026.

CTX-8371 Data Presentation Planned Full topline data for CTX-8371 Phase 1 study expected at medical meeting during first half of 2026.

Pipeline Expansion Initiated Planning cohort expansions this quarter for NSCLC and TNBC indications based on previously observed responses.

Increased G&A Anticipated Anticipate general and administrative expenses will increase as headcount grows to support overall business operations.

同業比較

売上高 (TTM)

RGNX

$161.32M

+91.3%

ARCT

$78.24M

-43.5%

LXRX

$70.86M

+1255.2%

粗利益率 (最新四半期)

ARCT

408.3%

-19.5pp

ATXS

100.0%

+0.0pp

BCYC

100.0%

+1705.8pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
CRVS	$1.49B	-98.0	-25.8%	1.3%
KOD	$1.42B	-6.5	-246.2%	28.5%
MLTX	$1.29B	-5.1	-67.1%	17.8%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月5日

EPS:-$0.10

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし